Clinical Trials Logo

Filter by:
NCT ID: NCT06130436 Recruiting - Liver Cancer Clinical Trials

Application of Perioperative Remote Ischemic Conditioning in Patients Undergoing Hepatectomy

Start date: October 25, 2023
Phase: N/A
Study type: Interventional

Our primary aim is to investigate whether perioperative remote ischemic conditioning (PRIC) as an adjunctive treatment can improve postoperative recovery in patients undergoing hepatectomy as an adjunct to standard treatment.

NCT ID: NCT06130332 Recruiting - Oral Cancer Clinical Trials

Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

Surgery is usually the first choice for early-stage oral squamous cell carcinoma (OSCC). However, there is currently a lack of consensus on whether patients with clinically negative cervical lymph nodes (N0) should undergo elective neck dissection (END) at the same time. About 20-30% of cT1-2N0M0 oral cancer patients have occult lymph node metastasis, and existing examination methods cannot accurately predict occult cervical lymph node metastasis. Therefore, most clinical retrospective and prospective studies recommend END for cN0 patients. Previous studies have found that no cancer cells were found in the cervical lymph nodes of 70% of patients after END. This unselective END can cause patients with accessory nerve dysfunction, neck scars, etc., and prolong hospitalization and surgery time. Exploring the treatment model for patients with early-stage oral squamous cell carcinoma is an urgent problem that needs to be solved. This study intends to conduct a study on the neoadjuvant treatment of tislelizumab, carboplatin, and albumin-bound paclitaxel. After neoadjuvant immunotherapy in patients with early-stage oral cancer (T1-2N0M0), the primary tumor is treated with standard surgical treatment. Comparison with A single-center exploratory clinical study of traditional oral cancer radical resection + selective neck lymphadenectomy was conducted to explore its effectiveness through the difference in 2-year disease-free survival (DFS). This research plan covers 40 patients with early-stage oral squamous cell carcinoma. They will be randomly divided into tislelizumab, chemotherapy combined with surgery (experimental group) and traditional surgery (control group) in a 1:1 ratio. The patients' tumors will be collected. Tissues, adjacent cancer tissues, whole blood samples, saliva samples, and matrix samples were used to observe the changes in imaging and pathology compared with treatment. At the same time, the clinical information of the patients was collected, such as quality of life indicators such as judgment function, pathological grading, staging, treatment, Spine, serology, imaging, etc., mainly to evaluate the 2-year event-free survival (EFS) between the experimental group and Weather Forecast, and the 3-year overall survival (OS) and patient quality of life between the experimental group and Weather Forecast.

NCT ID: NCT06130319 Recruiting - Clinical trials for Chronic Heart Failure

Correlation of Disease Management and Quality of Life in Patients With Chronic Heart Failure and Their Family Caregivers

Start date: November 2023
Phase:
Study type: Observational

This study intends to investigate the current status of disease management and quality of life of patients with chronic heart failure and their family caregivers, explore the relationship between the two sides of disease management and quality of life, help nurses identify the influencing factors of quality of life of patients with chronic heart failure and their family caregivers, and carry out family-centered care in the future. This study intends to investigate the current status of disease management and quality of life of patients with chronic heart failure and their family caregivers, explore the relationship between disease management and quality of life of both sides, and help nurses identify the influencing factors affecting the quality of life of patients with chronic heart failure and their family caregivers, so as to carry out family-centered care in the future. To provide theoretical basis for improving the quality of life of both parties.

NCT ID: NCT06130306 Recruiting - Clinical trials for Urinary Incontinence Following Surgical Procedure

A PSM Analysis to Evaluate Electrical Pudendal Nerve Stimulation for PPI

Start date: December 1, 2023
Phase:
Study type: Observational

The goal of this propensity score matching study is to compare the posttreatment outcomes of post-radical prostatectomy Incontinence patients undergoing either electrical pudendal nerve stimulation or pelvic floor muscle training combined with transanal electrical stimulation.

NCT ID: NCT06129955 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

Start date: November 11, 2023
Phase: Phase 2
Study type: Interventional

Through the neoadjuvant treatment with a combination of Pucotenlimab and Lenvatinib, it eventually enables the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who have indications for nephron-sparing surgery but face significant difficulty in kidney preservation (T1b with an endophytic component ≥75% or T2).

NCT ID: NCT06129942 Recruiting - Parkinson Disease Clinical Trials

Light Therapy in Parkinson's Disease

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aim of this randomized controlled trial (RCT) is to clarify the effect of bright light therapy on motor symptoms and sleep disorders in patients with Parkinson's disease.

NCT ID: NCT06129201 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging

Start date: November 15, 2023
Phase:
Study type: Observational

Nasopharyngeal cancer is common in China, Southeast Asia, and North Africa, and is usually associated with Epstein-Barr virus (EBV) infection. Using EBV specific antibodies or EBV DNA screening can increase the proportion of patients diagnosed with early nasopharyngeal carcinoma from approximately 20% to over 70%. However, the application of nasopharyngeal carcinoma screening in clinical practice is hindered by low positive predictive values, even in areas where the EB virus is prevalent in China, the positive predictive value is only 4.8%. Therefore, there is an urgent need to identify new biomarkers or strategies with high sensitivity and positive predictive value for nasopharyngeal carcinoma screening. A study published in the Lancet sub journal 《eClinicalMedicine》 in 2023 showed that a tongue image model based on machine learning can serve as a stable diagnostic method for gastric cancer (AUC=0.89), and has been clinically validated in multiple centers. This study inspires researchers to introduce artificial intelligence machine learning technology into the diagnosis and treatment of nasopharyngeal cancer. In summary, this plan explores the establishment of tongue image machine learning models in nasopharyngeal carcinoma patients to help improve the positive predictive value of nasopharyngeal carcinoma screening.

NCT ID: NCT06128837 Recruiting - Clinical trials for Relapsed Small Cell Lung Cancer

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Start date: March 3, 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter,randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)

NCT ID: NCT06128785 Not yet recruiting - Colorectal Cancer Clinical Trials

Electroacupuncture (EA) Promotes Gastrointestinal Functional Recovery After Radical Colorectal Cancer Surgery

Start date: November 6, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to verify the efficacy of electroacupuncture in accelerating the recovery of gastrointestinal function after colorectal cancer surgery. The main questions it aims to answer are: - Whether electroacupuncture can accelerate the recovery of gastrointestinal function in patients after colorectal cancer surgery. - Whether electroacupuncture intervention is safe for postoperative colorectal cancer patients. Participants will be randomized into 3 groups: The conventional control group will receive postoperative rehydration and nutritional support, correction of acid-base imbalance and electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatments. In the electroacupuncture group, acupuncture will be performed within 6 hours after surgery on the basis of the conventional control group. Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). Both after obtaining Qi, and unilaterally connected to the electroacupuncture instrument for electrical stimulation, the current frequency is continuous wave 5 Hz, the intensity of stimulation was as the patient tolerated, each time lasting 30 min. Acupuncture stimulation was given every 12 h. The course of treatment was terminated postoperatively until the fourth postoperative day (d0-d4) or until the patient showed the first postoperative anal exhaust or continued until the fourth day. The sham acupuncture group will based on the conventional control group, using a blunt-tipped needle tip that do not pierce the adhesive pad.

NCT ID: NCT06128681 Recruiting - Clinical trials for Mediastinal Diseases

Diagnosis and Comprehensive Treatment of Mediastinal Interventional Technique

Start date: November 10, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn abou Whether patients undergoing mediastinal disease diagnosis and combined treatment with intrapacial ultrasound-guided mediastinal opening techniques have greater clinical benefit. The participants were physically ill. The main questions it aims to answer are: - Whether the mediastinal ultrasound-guided mediastinal opening technique is more beneficial for the diagnosis of benign or malignant mediastinal diseases. - Does the mediastinal ultrasound-guided mediastinal opening technique benefit the patient by ablating mediastinal masses using freezing, laser, or other means. Mediastinal diseases were diagnosed by lymph node biopsy combined with NGS, ROSE and other techniques using transairway ultrasound-guided mediastinal opening technique. Ablation of mediastinal malignancies is performed using techniques such as freezing or laser. Researchers will compare the experimental group with mediastinal opening and the control group without mediastinal opening to see if Mediastinal open technique benefits patients.